Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
|ClinicalTrials.gov Identifier: NCT00004832|
Recruitment Status : Completed
First Posted : February 25, 2000
Last Update Posted : March 25, 2015
OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS).
II. Determine the side-effects and benefits associated with DAP.
|Condition or disease||Intervention/treatment|
|Lambert-Eaton Myasthenic Syndrome||Drug: 3,4-diaminopyridine|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||26 participants|
|Study Start Date :||August 1994|
|Estimated Study Completion Date :||June 1998|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004832
|Study Chair:||Donald B. Sanders||Duke University|